Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 first-line zanidatamab-based therapy study in HER2-positive gastroesophageal adenocarcinoma
CTR20212727Phase 3Active
- Sponsor
- BeOne Medicines
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of zanidatamab, tislelizumab in gastroesophageal junction adenocarcinoma, sponsored by BeOne Medicines. Started Jan 2022; status: active.
02
Drugs
zanidatamabtislelizumab
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20212727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212727.